Building a Resilient Drug Supply Chain

Building a Resilient Drug Supply Chain 
Duke-Margolis Center Webinar 
April 19, 2021 | 12:00-2:00pm 

The COVID-19 pandemic has highlighted the vulnerability of the US drug supply chain.  Even before the pandemic, drug shortages were a pervasive and persistent problem, affecting critical drugs to treat patients in hospitals and emergency rooms. With the onset of the pandemic, these challenges have grown, with healthcare providers struggling to find the drugs and supplies they needed to effectively treat and manage patients with COVID-19. 

Given these challenges, there have been growing calls to increase the resilience of the US drug supply chain.  Resilient drug supply chains can limit the risk of drug shortages, protect patient health, and ensure preparedness for pandemics and other threats to health and national security. Recognizing the importance of a resilient supply chain, the Biden administration issued an executive order in February calling for an assessment of the resilience of America’s supply chains, including the supply chain for drugs.   

The Duke-Margolis Center for Health Policy is convening a public webinar to discuss how to build a more resilient drug supply chain.  During this webinar, experts, including drug manufacturers and policymakers, will describe the challenges we face in building a resilient drug supply chain, potential approaches to build a more robust, responsive, and resilient supply chain, and how we can assess our progress towards supply chain resilience.